May 2020, Drugs Monitor, Page 3

(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery

May 13, 2020

(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 – 2 SUBTITLE: An initial report from the Vall d’Hebron COVID-19 prospective cohort 3 study. https://doi.org/10.1101/2020.05.07.20094599… Continue reading "(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery"

(12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells

May 13, 2020

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate https://doi.org/10.1101/2020.05.12.090035 Authors identified 24 FDA-approved drugs which exhibited substantial antiviral effect against SARS-CoV-2 in Vero cells. They developed… Continue reading "(12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells"

(11 May 2020) Tocilizumab- reduced ICU admissions and deaths

May 12, 2020

Tocilizumab therapy reduced intensive care unit admissions and/ormortality in COVID-19 patients https://doi.org/doi:10.1016/j.medmal.2020.05.001 In a retrospective case-control study with a small sample size, death and/or ICU admissions were higher in patients without Tocilizumab (TCZ) than in the TCZ group (72% vs… Continue reading "(11 May 2020) Tocilizumab- reduced ICU admissions and deaths"

(11 May 2020) Hydroxychloroquine- not significantly associated with differences in in-hospital mortality

May 12, 2020

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State https://jamanetwork.com/journals/jama/fullarticle/2766117 Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or… Continue reading "(11 May 2020) Hydroxychloroquine- not significantly associated with differences in in-hospital mortality"

(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good

May 12, 2020

Observation of the efficacy and safety of lopinavir / ritonavir and abidor in the treatment of new coronavirus pneumonia http://rs.yiigle.com/yufabiao/1193931.htm This paper describes retrospective analysis of the clinical data of 178 patients diagnosed as COVID-19 , and divided into 59… Continue reading "(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good"

(08 May 2020) Remdesivir- Faster recovery rates

May 11, 2020

Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study https://doi.org/10.1101/2020.05.02.20088559 Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and… Continue reading "(08 May 2020) Remdesivir- Faster recovery rates"

(08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients

May 11, 2020

Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study https://doi.org/10.1101/2020.05.01.20086694 In a retrospective study in patients hospitalized with COVID-19 famotidine use was associated with a significantly reduced risk of clinical… Continue reading "(08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients"

(08 May 2020)- Hydroxychloroquine- addition of zinc to HCQ, and AZT proves to be more efficacious

May 11, 2020

Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients https://doi.org/10.1101/2020.05.02.20080036 In a retrospective observational study to compare hospital outcomes among patients who received hydroxychloroquine and azithromycin plus zinc versus hydroxychloroquine and azithromycin alone, it… Continue reading "(08 May 2020)- Hydroxychloroquine- addition of zinc to HCQ, and AZT proves to be more efficacious"

(08 May 2020) Clinical trial findings- early triple antiviral combination effective

May 9, 2020

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext In a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19, shortening in… Continue reading "(08 May 2020) Clinical trial findings- early triple antiviral combination effective"

(07 May 2020) Ivermectin- approved dose might not work for COVID 19

May 7, 2020

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1889 Ivermectin is unlikely to reach the IC50 in lungs after oral administration of the approved dose or doses 10x higher than the approved… Continue reading "(07 May 2020) Ivermectin- approved dose might not work for COVID 19"

Month: May 2020